17 results on '"Geckin, B."'
Search Results
2. Differences in Immune Responses in Individuals of Indian and European Origin: Relevance for the COVID-19 Pandemic
- Author
-
Geckin, B., Zoodsma, Martijn, Kilic, Gizem, Debisarun, P., Rakshit, Srabanti, Baltissen, M.P., Adiga, Vasista, Martens, Joost H.A., Domínguez-Andrés, J., Li, Y., Vyakarnam, Annapurna, Netea, M.G., Geckin, B., Zoodsma, Martijn, Kilic, Gizem, Debisarun, P., Rakshit, Srabanti, Baltissen, M.P., Adiga, Vasista, Martens, Joost H.A., Domínguez-Andrés, J., Li, Y., Vyakarnam, Annapurna, and Netea, M.G.
- Abstract
28 maart 2023, Contains fulltext : 291030.pdf (Publisher’s version ) (Open Access)
- Published
- 2023
3. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial.
- Author
-
Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Mourik, D. van, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, Netea, M.G., Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Mourik, D. van, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, and Netea, M.G.
- Abstract
01 juni 2023, Item does not contain fulltext, BACKGROUND: Novel mRNA-based vaccines have been used to protect against SARS-CoV-2, especially in vulnerable populations who also receive an annual influenza vaccination. The TACTIC study investigated potential immune interference between the mRNA COVID-19 booster vaccine and the quadrivalent influenza vaccine, and determined if concurrent administration would have effects on safety or immunogenicity. METHODS: TACTIC was a single-blind, placebo-controlled randomized clinical trial conducted at the Radboud University Medical Centre, the Netherlands. Individuals ≥60 years, fully vaccinated against COVID-19 were eligible for participation and randomized into one of four study groups: 1) 0.5 ml influenza vaccination Vaxigrip Tetra followed by 0.3 ml BNT162b2 COVID-19 booster vaccination 21 days later, (2) COVID-19 booster vaccination followed by influenza vaccination, (3) influenza vaccination concurrent with the COVID-19 booster vaccination, and (4) COVID-19 booster vaccination only (reference group). Primary outcome was the geometric mean concentration (GMC) of IgG against the spike (S)-protein of the SARS-CoV-2 virus, 21 days after booster vaccination. We performed a non-inferiority analysis of concurrent administration compared to booster vaccines alone with a predefined non-inferiority margin of -0.3 on the log10-scale. FINDINGS: 154 individuals participated from October, 4, 2021, until November, 5, 2021. Anti-S IgG GMCs for the co-administration and reference group were 1684 BAU/ml and 2435 BAU/ml, respectively. Concurrent vaccination did not meet the criteria for non-inferiority (estimate -0.1791, 95% CI -0.3680 to -0.009831) and antibodies showed significantly lower neutralization capacity compared to the reference group. Reported side-effects were mild and did not differ between study groups. INTERPRETATION: Concurrent administration of both vaccines is safe, but the quantitative and functional antibody responses were marginally lower compared to booster vaccin
- Published
- 2023
4. Timing and sequence of vaccination against COVID-19 and influenza - Author's reply.
- Author
-
Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, Netea, M.G., Dulfer, E.A., Geckin, B., Taks, E.J.M., GeurtsvanKessel, C.H., Dijkstra, H.I., Emst, J.E. van, Gaast-de Jongh, C.E. van der, Koopmans, P.C., Dominguez Andres, J., Crevel, R. van, Maat, J.S. van de, Jonge, M.I. de, and Netea, M.G.
- Abstract
01 juli 2023, Item does not contain fulltext
- Published
- 2023
5. The fungal-derived compound AM3 modulates pro-inflammatory cytokine production and skews the differentiation of human monocytes
- Author
-
Geckin, B., Kilic, G., Debisarun, A., Föhse, F.K., Rodriguez-Luna, Azahara, Fernandez-Gonzalez, Pablo, Sanchez, Ana Lopez, Dominguez Andres, J., Geckin, B., Kilic, G., Debisarun, A., Föhse, F.K., Rodriguez-Luna, Azahara, Fernandez-Gonzalez, Pablo, Sanchez, Ana Lopez, and Dominguez Andres, J.
- Abstract
Item does not contain fulltext
- Published
- 2023
6. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
- Author
-
Föhse, F.K., Geckin, B., Zoodsma, M., Kilic, G., Liu, Zhaoli, Röring, R.J., Overheul, G.J., Maat, J.S. van de, Bulut, Ö, Hoogerwerf, J.J., Oever, J. ten, Simonetti, E.R., Schaal, H., Adams, O., Muller, L., Ostermann, P.N., Veerdonk, F.L. van de, Joosten, L.A.B., Haagmans, B.L., Crevel, R. van, Rij, R.P. van, GeurtsvanKessel, Corine H., Jonge, M.I. de, Li, Y., Dominguez Andres, J., Netea, M.G., Föhse, F.K., Geckin, B., Zoodsma, M., Kilic, G., Liu, Zhaoli, Röring, R.J., Overheul, G.J., Maat, J.S. van de, Bulut, Ö, Hoogerwerf, J.J., Oever, J. ten, Simonetti, E.R., Schaal, H., Adams, O., Muller, L., Ostermann, P.N., Veerdonk, F.L. van de, Joosten, L.A.B., Haagmans, B.L., Crevel, R. van, Rij, R.P. van, GeurtsvanKessel, Corine H., Jonge, M.I. de, Li, Y., Dominguez Andres, J., and Netea, M.G.
- Abstract
Contains fulltext : 297155.pdf (Publisher’s version ) (Open Access)
- Published
- 2023
7. Trained immunity: implications for vaccination
- Author
-
Geckin, B., Föhse, F.K., Dominguez Andres, J., Netea, M.G., Geckin, B., Föhse, F.K., Dominguez Andres, J., and Netea, M.G.
- Abstract
Contains fulltext : 282342.pdf (Publisher’s version ) (Open Access), The concept that only adaptive immunity can build immunological memory has been challenged in the past decade. Live attenuated vaccines such as the Bacillus Calmette-Guérin, measles-containing vaccines, and the oral polio vaccine have been shown to reduce overall mortality beyond their effects attributable to the targeted diseases. After an encounter with a primary stimulus, epigenetic and metabolic reprogramming of bone marrow progenitor cells and functional changes of tissue immune cell populations result in augmented immune responses against a secondary challenge. This process has been termed trained immunity. This review describes the mechanisms leading to trained immunity and summarizes the most important developments from the past few years.
- Published
- 2022
8. The fungal-derived compound AM3 modulates pro-inflammatory cytokine production and skews the differentiation of human monocytes.
- Author
-
Geckin B, Kilic G, Debisarun PA, Föhse K, Rodríguez-Luna A, Fernández-González P, Sánchez AL, and Domínguez-Andrés J
- Subjects
- Humans, Aged, Inflammation, Cell Differentiation, Cytokines, Monocytes, Leukocytes, Mononuclear
- Abstract
The proper functioning of the immune system depends on an appropriate balance between pro-inflammation and anti-inflammation. When the balance is disrupted and the system is excessively biased towards inflammation, immune responses cannot return within the normal range, which favors the onset of diseases of autoimmune or inflammatory nature. In this scenario, it is fundamental to find new compounds that can help restore this balance and contribute to the normal functioning of the immune system in humans. Here, we show the properties of a fungal compound with a strong safety profile in humans, AM3, as an immunomodulatory molecule to decrease excessive cytokine production in human cells. Our results present that AM3 treatment of human peripheral blood mononuclear cells and monocytes decreased their pro-inflammatory cytokine secretion following the challenge with bacterial lipopolysaccharide. Additionally, AM3 skewed the differentiation profile of human monocytes to macrophages towards a non-inflammatory phenotype without inducing tolerance, meaning these cells kept their capacity to respond to different stimuli. These effects were similar in young and elderly individuals. Thus, the fungal compound, AM3 may help reduce excessive immune activation in inflammatory conditions and keep the immune responses within a normal homeostatic range, regardless of the age of the individual., Competing Interests: AR-L and AL were full-time employed by Cantabria Labs. PF-G is a scientific adviser at Cantabria Labs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Geckin, Kilic, Debisarun, Föhse, Rodríguez-Luna, Fernández-González, Sánchez and Domínguez-Andrés.)
- Published
- 2023
- Full Text
- View/download PDF
9. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses.
- Author
-
Föhse K, Geckin B, Zoodsma M, Kilic G, Liu Z, Röring RJ, Overheul GJ, van de Maat J, Bulut O, Hoogerwerf JJ, Ten Oever J, Simonetti E, Schaal H, Adams O, Müller L, Ostermann PN, van de Veerdonk FL, Joosten LAB, Haagmans BL, van Crevel R, van Rij RP, GeurtsvanKessel C, de Jonge MI, Li Y, Domínguez-Andrés J, and Netea MG
- Abstract
The mRNA-based BNT162b2 protects against severe disease and mortality caused by SARS-CoV-2 via induction of specific antibody and T-cell responses. Much less is known about its broad effects on immune responses against other pathogens. Here, we investigated the adaptive immune responses induced by BNT162b2 vaccination against various SARS-CoV-2 variants and its effects on the responsiveness of immune cells upon stimulation with heterologous stimuli. BNT162b2 vaccination induced effective humoral and cellular immunity against SARS-CoV-2 that started to wane after six months. We also observed long-term transcriptional changes in immune cells after vaccination. Additionally, vaccination with BNT162b2 modulated innate immune responses as measured by inflammatory cytokine production after stimulation - higher IL-1/IL-6 release and decreased IFN-α production. Altogether, these data expand our knowledge regarding the overall immunological effects of this new class of vaccines and underline the need for additional studies to elucidate their effects on both innate and adaptive immune responses., Competing Interests: Declaration of Competing Interest M.G.N and L.A.B.J are scientific founders of TTxD and Lemba., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Timing and sequence of vaccination against COVID-19 and influenza - Author's reply.
- Author
-
Dulfer EA, Geckin B, Taks EJM, GeurtsvanKessel CH, Dijkstra H, van Emst L, van der Gaast-de Jongh CE, Koopmans PC, Domínguez-Andrés J, van Crevel R, van de Maat JS, de Jonge MI, and Netea MG
- Abstract
Competing Interests: MGN is a scientific founder of TTxD, Lemba and BioTrip, and a member of the TTxD scientific advisory board. MGN has received research grants from TTxD and GSK. The TACTIC trial was conducted with the ZonMw COVID-19 programme. The other authors have no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
11. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial.
- Author
-
Dulfer EA, Geckin B, Taks EJM, GeurtsvanKessel CH, Dijkstra H, van Emst L, van der Gaast-de Jongh CE, van Mourik D, Koopmans PC, Domínguez-Andrés J, van Crevel R, van de Maat JS, de Jonge MI, and Netea MG
- Abstract
Background: Novel mRNA-based vaccines have been used to protect against SARS-CoV-2, especially in vulnerable populations who also receive an annual influenza vaccination. The TACTIC study investigated potential immune interference between the mRNA COVID-19 booster vaccine and the quadrivalent influenza vaccine, and determined if concurrent administration would have effects on safety or immunogenicity., Methods: TACTIC was a single-blind, placebo-controlled randomized clinical trial conducted at the Radboud University Medical Centre, the Netherlands. Individuals ≥60 years, fully vaccinated against COVID-19 were eligible for participation and randomized into one of four study groups: 1) 0.5 ml influenza vaccination Vaxigrip Tetra followed by 0.3 ml BNT162b2 COVID-19 booster vaccination 21 days later, (2) COVID-19 booster vaccination followed by influenza vaccination, (3) influenza vaccination concurrent with the COVID-19 booster vaccination, and (4) COVID-19 booster vaccination only (reference group). Primary outcome was the geometric mean concentration (GMC) of IgG against the spike (S)-protein of the SARS-CoV-2 virus, 21 days after booster vaccination. We performed a non-inferiority analysis of concurrent administration compared to booster vaccines alone with a predefined non-inferiority margin of -0.3 on the log10-scale., Findings: 154 individuals participated from October, 4, 2021, until November, 5, 2021. Anti-S IgG GMCs for the co-administration and reference group were 1684 BAU/ml and 2435 BAU/ml, respectively. Concurrent vaccination did not meet the criteria for non-inferiority (estimate -0.1791, 95% CI -0.3680 to -0.009831) and antibodies showed significantly lower neutralization capacity compared to the reference group. Reported side-effects were mild and did not differ between study groups., Interpretation: Concurrent administration of both vaccines is safe, but the quantitative and functional antibody responses were marginally lower compared to booster vaccination alone. Lower protection against COVID-19 with concurrent administration of COVID-19 and influenza vaccination cannot be excluded, although additional larger studies would be required to confirm this., Trial Registration Number: EudraCT: 2021-002186-17., Funding: The study was supported by the ZonMw COVID-19 Programme., Competing Interests: MGN is a scientific founder of TTxD, Lemba and BioTrip, and a member of the TTxD scientific advisory board. MGN has received research grants from TTxD and GSK. The other authors have no conflicts of interest., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
12. Differences in Immune Responses in Individuals of Indian and European Origin: Relevance for the COVID-19 Pandemic.
- Author
-
Geckin B, Zoodsma M, Kilic G, Debisarun PA, Rakshit S, Adiga V, Ahmed A, Parthiban C, Kumar NC, D'Souza G, Baltissen MP, Martens JHA, Domínguez-Andrés J, Li Y, Vyakarnam A, and Netea MG
- Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, large differences in susceptibility and mortality due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported between populations in Europe and South Asia. While both host and environmental factors (including Mycobacterium bovis BCG vaccination) have been proposed to explain this, the potential biological substrate of these differences is unknown. We purified peripheral blood mononuclear cells from individuals living in India and the Netherlands at baseline and 10 to 12 weeks after BCG vaccination. We compared chromatin accessibility between the two populations at baseline, as well as gene transcription profiles and cytokine production capacities upon stimulation. The chromatin accessibility of genes important for adaptive immunity was higher in the Indians than in the Europeans, while the latter had more accessible chromatin regions in genes of the innate immune system. At the transcriptional level, we observed that the Indian volunteers displayed a more tolerant immune response to stimulation, in contrast to a more exaggerated response in the Europeans. BCG vaccination strengthened the tolerance program in the Indians but not in the Europeans. These differences may partly explain the different impact of COVID-19 on the two populations. IMPORTANCE In this study, we assessed the differences in immune responses in individuals from India and Europe. This aspect is of great relevance, because of the described differences in morbidity and mortality between India and Europe during the pandemic. We found a significant difference in chromatin accessibility in immune cells from the two populations, followed by a more balanced and effective response in individuals from India. These exciting findings represent a very important piece of the puzzle for understanding the COVID-19 pandemic at a global level.
- Published
- 2023
- Full Text
- View/download PDF
13. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults.
- Author
-
Rakshit S, Adiga V, Ahmed A, Parthiban C, Chetan Kumar N, Dwarkanath P, Shivalingaiah S, Rao S, D'Souza G, Dias M, Maguire TJA, Doores KJ, Zoodsma M, Geckin B, Dasgupta P, Babji S, van Meijgaarden KE, Joosten SA, Ottenhoff THM, Li Y, Netea MG, Stuart KD, De Rosa SC, McElrath MJ, and Vyakarnam A
- Subjects
- Humans, Young Adult, Adjuvants, Immunologic, Chromatin, Immunity, Interleukin-2, SARS-CoV-2, Tumor Necrosis Factor-alpha, Vaccination, BCG Vaccine, COVID-19 prevention & control, COVID-19 Vaccines immunology
- Abstract
This proof-of-concept study tested if prior BCG revaccination can qualitatively and quantitively enhance antibody and T-cell responses induced by Oxford/AstraZeneca ChAdOx1nCoV-19 or COVISHIELD™, an efficacious and the most widely distributed vaccine in India. We compared COVISHIELD™ induced longitudinal immune responses in 21 BCG re-vaccinees (BCG-RV) and 13 BCG-non-revaccinees (BCG-NRV), all of whom were BCG vaccinated at birth; latent tuberculosis negative and SARS-CoV-2 seronegative prior to COVISHIELD™ vaccination. Compared to BCG-NRV, BCG-RV displayed significantly higher and persistent spike-specific neutralizing (n) Ab titers and polyfunctional CD4+ and CD8+ T-cells for eight months post COVISHIELD™ booster, including distinct CD4+IFN-γ+ and CD4+IFN-γ- effector memory (EM) subsets co-expressing IL-2, TNF-α and activation induced markers (AIM) CD154/CD137 as well as CD8+IFN-γ+ EM,TEMRA (T cell EM expressing RA) subset combinations co-expressing TNF-α and AIM CD137/CD69. Additionally, elevated nAb and T-cell responses to the Delta mutant in BCG-RV highlighted greater immune response breadth. Mechanistically, these BCG adjuvant effects were associated with elevated markers of trained immunity, including higher IL-1β and TNF-α expression in CD14+HLA-DR+monocytes and changes in chromatin accessibility highlighting BCG-induced epigenetic changes. This study provides first in-depth analysis of both antibody and memory T-cell responses induced by COVISHIELD™ in SARS-CoV-2 seronegative young adults in India with strong evidence of a BCG-induced booster effect and therefore a rational basis to validate BCG, a low-cost and globally available vaccine, as an adjuvant to enhance heterologous adaptive immune responses to current and emerging COVID-19 vaccines., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Rakshit, Adiga, Ahmed, Parthiban, Chetan Kumar, Dwarkanath, Shivalingaiah, Rao, D’Souza, Dias, Maguire, Doores, Zoodsma, Geckin, Dasgupta, Babji, van Meijgaarden, Joosten, Ottenhoff, Li, Netea, Stuart, De Rosa, McElrath and Vyakarnam.)
- Published
- 2022
- Full Text
- View/download PDF
14. Trained immunity: implications for vaccination.
- Author
-
Geckin B, Konstantin Föhse F, Domínguez-Andrés J, and Netea MG
- Subjects
- Adaptive Immunity, Humans, Immunity, Innate, Immunologic Memory, Vaccination, BCG Vaccine, Mycobacterium bovis
- Abstract
The concept that only adaptive immunity can build immunological memory has been challenged in the past decade. Live attenuated vaccines such as the Bacillus Calmette-Guérin, measles-containing vaccines, and the oral polio vaccine have been shown to reduce overall mortality beyond their effects attributable to the targeted diseases. After an encounter with a primary stimulus, epigenetic and metabolic reprogramming of bone marrow progenitor cells and functional changes of tissue immune cell populations result in augmented immune responses against a secondary challenge. This process has been termed trained immunity. This review describes the mechanisms leading to trained immunity and summarizes the most important developments from the past few years., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
15. When platelets meet candidalysin: "We just Wnt to have fun".
- Author
-
Bulut O, Geckin B, and Domínguez-Andrés J
- Subjects
- Candida albicans, Humans, Blood Platelets, Fungal Proteins
- Published
- 2022
- Full Text
- View/download PDF
16. Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency.
- Author
-
Surucu Yilmaz N, Bilgic Eltan S, Kayaoglu B, Geckin B, Heredia RJ, Sefer AP, Kiykim A, Nain E, Kasap N, Dogru O, Yucelten AD, Cinel L, Karasu G, Yesilipek A, Sozeri B, Kaya GG, Yilmaz IC, Baydemir I, Aydin Y, Cansen Kahraman D, Haimel M, Boztug K, Karakoc-Aydiner E, Gursel I, Ozen A, Baris S, and Gursel M
- Subjects
- Child, Granulocytes metabolism, Humans, I-kappa B Kinase genetics, I-kappa B Kinase metabolism, Leukocytes, Mononuclear metabolism, Male, Ectodermal Dysplasia genetics, Neutrophils
- Abstract
NF-κB essential modulator (NEMO, IKK-γ) deficiency is a rare combined immunodeficiency caused by mutations in the IKBKG gene. Conventionally, patients are afflicted with life threatening recurrent microbial infections. Paradoxically, the spectrum of clinical manifestations includes severe inflammatory disorders. The mechanisms leading to autoinflammation in NEMO deficiency are currently unknown. Herein, we sought to investigate the underlying mechanisms of clinical autoinflammatory manifestations in a 12-years old male NEMO deficiency (EDA-ID, OMIM #300,291) patient by comparing the immune profile of the patient before and after hematopoietic stem cell transplantation (HSCT). Response to NF-kB activators were measured by cytokine ELISA. Neutrophil and low-density granulocyte (LDG) populations were analyzed by flow cytometry. Peripheral blood mononuclear cells (PBMC) transcriptome before and after HSCT and transcriptome of sorted normal-density neutrophils and LDGs were determined using the NanoString nCounter gene expression panels. ISG15 expression and protein ISGylation was based on Immunoblotting. Consistent with the immune deficiency, PBMCs of the patient were unresponsive to toll-like and T cell receptor-activators. Paradoxically, LDGs comprised 35% of patient PBMCs and elevated expression of genes such as MMP9, LTF, and LCN2 in the granulocytic lineage, high levels of IP-10 in the patient's plasma, spontaneous ISG15 expression and protein ISGylation indicative of a spontaneous type I interferon (IFN) signature were observed, all of which normalized after HSCT. Collectively, our results suggest that type I IFN signature observed in the patient, dysregulated LDGs and spontaneously activated neutrophils, potentially contribute to tissue damage in NEMO deficiency., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
17. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
- Author
-
Kayaoglu B, Kasap N, Yilmaz NS, Charbonnier LM, Geckin B, Akcay A, Eltan SB, Ozturk G, Ozen A, Karakoc-Aydiner E, Chatila TA, Gursel M, and Baris S
- Subjects
- Alleles, Child, Preschool, Combined Modality Therapy, Cytokines metabolism, Diagnosis, Differential, Female, Genotype, Humans, Immune System Diseases diagnosis, Immunophenotyping, Phenotype, Phosphorylation, STAT1 Transcription Factor metabolism, Treatment Outcome, Gain of Function Mutation, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Immune System Diseases etiology, Immune System Diseases therapy, Janus Kinase Inhibitors therapeutic use, Nitriles therapeutic use, Pyrazoles therapeutic use, Pyrimidines therapeutic use, STAT1 Transcription Factor genetics
- Abstract
Purpose: Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established. Herein, we aimed to unravel the effect of ruxolitinib as a bridge therapy in a patient with sporadic STAT1 T385M mutation to manage infections and other disease manifestations., Methods: Peripheral blood mononuclear cells were isolated from the patient prior to, during ruxolitinib treatment and 6 months after HSCT. IFN-β-induced STAT1 phosphorylation/dephosphorylation levels and PMA/ionomycin-stimulated intracellular IL-17A/IFN-γ production in CD4
+ T cells were evaluated. Differentially expressed genes between healthy controls and the patient prior to, during ruxolitinib treatment and post-transplantation were investigated using Nanostring nCounter Profiling Panel., Results: Ruxolitinib provided favorable responses by controlling candidiasis and autoimmune hemolytic anemia in the patient. Dysregulation in STAT1 phosphorylation kinetics improved with ruxolitinib treatment and was completely normalized after transplantation. TH 17 deficiency persisted after ruxolitinib treatment, but normalized following HSCT. Consistent with the impairment in JAK/STAT signaling, multiple immune related pathways were found to be dysregulated in the patient. At baseline, genes related to type I IFN-related pathways, antigen processing, T-cell and B-cell functions were upregulated, while NK-cell function and cytotoxicity related genes were downregulated. Dysregulated gene expression was partially improved with ruxolitinib treatment and normalized after transplantation., Conclusion: Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.